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A Critical Appraisal of the Principal Guidelines for Neurogenic Lower Urinary Tract Dysfunction 
Using the AGREE II Instrument. 
ABSTRACT 
AIMS: The process of identifying research questions, synthesising and interpreting evidence, and 
weight given to health economics differs between the clinical guidelines (CGs) for neurogenic lower 
urinary tract dysfunction (NLUTD). Consequently, the quality also varies which can have implications 
for clinical practice.  
METHODS: We used the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument to 
assess the quality of the National Institute for Health and Care Excellent (NICE), European 
Association of Urology (EAU) and the International Consultations on Incontinence (ICI) CGs on 
neurogenic bladder.  
RESULTS: The NICE CGs were deemed to be of the highest quality (overall score of 92%). NICE were 
the only guidelines to systematically incorporate cost-effectiveness research into their 
recommendations. The EAU CGs received an overall score of 83% and the ICI CGs achieved the 
lowest overall score (75%). The highest scoring domain amongst all the CGs was scope purpose 
(86%) and the lowest scoring domain was applicability (69%). All guidelines were recommended for 
use (mostly with some modifications).  
CONCLUSIONS: All CGs had their inherent advantages and disadvantages, though all were still 
deemed to be of high quality. Incorporating cost-effectiveness research would be near impossible 
for guidelines with a broad-country remit. Incorporating the AGREE II instrument in the development 
of CGs and better collaboration between the ICI, NICE and EAU could improve the quality, and 
consistency between NLUTD CGs and ultimately improve health outcomes for this important patient 
group. 
INTRODUCTION Neurogenic lower urinary tract dysfunction (NLUTD) is a urological dysfunction that 
occurs as a consequence of neurologic disease. It affects approximately 27-85% of patients with 
Parkinson’s disease (PD), 70-84% with spinal cord injuries (SCI), up to 70% of those with stroke, and 
40–90% of persons with multiple sclerosis (MS) 1-3. Individuals with NLUTD may experience neurogenic 
detrusor overactivity (NDO), which is characterised by increased frequency of micturition, urinary 
urgency (if sensation is unaffected by the underlying condition) and urinary incontinence. Alternatively, 
patients may have problems in voiding, with symptoms including hesitancy, a slow urinary stream, the 
need to strain and urinary retention. NLUTD has a substantial impact on patients’ health related 
quality of life (HRQoL) and use of healthcare resources due to bladder symptoms and associated 
sequela 4.  
The National Academy of Medicine (NAM) (formerly known as the Institute of Medicine (IOM)) was 
founded in 1970, under the charter of the National Academy of Sciences. The organisation comprises 
of 80 prominent members in the field of medicine and beyond5. The NAM define clinical guidelines 
(CGs) as “statements that include recommendations intended to optimize patient care that are 
informed by a systematic review of evidence and an assessment of the benefits and harms of 
alternative care options”.6 CGs are an important tool in establishing evidence-based medicine (EBM) 
in clinical practice, and adequate implementation can improve patient outcomes, as well as 
inefficiencies and inequity across care institutions 7. The three most prominent organisations that 
produce CGs for the management of NLUTD are the National Institute for Health and Care Excellent 
(NICE), the European Association of Urology (EAU) and the International Consultations on 
Incontinence (ICI). 8-10 
The process of identifying research questions, synthesising and interpreting evidence differs between 
CGs. These differences are often the result of differing goals, financial resources and membership of 
organisations. Consequently, the quality also varies, which can have implications for clinical practice. 
For example, some developers employ rigorous systematic reviewing techniques whilst other CGs 
weigh more heavily on expert opinion. Another key differentiating factor is the weight given to health 
economic evidence. Whereas some CGs include well-integrated economic analysis to determine the 
most cost-effective management strategies, others focus solely on clinical outcomes.   
The Appraisal of Guidelines for Research and Evaluation (AGREE) collaboration defines good quality 
CGs as “the confidence that the potential biases of guideline development have been addressed 
adequately and that the recommendations are both internally and externally valid, and are feasible 
for practice”. 11 They developed the AGREE II instrument to critically appraise the transparency and 
methodological rigour of CG development. 11 The instrument was utilised in the current study to 
determine the quality of available NLUTD CGs, and identify where potential improvements could be 
made. 
MATERIALS AND METHODS 
AGREE II Instrument 
Two appraisers (AJ, ES) independently assessed the quality of the NLUTD CGs using the AGREE II 
instrument. The instrument consists of 23 items, grouped into six domains: (1) scope and purpose 
(items 1-3), (2) stakeholder involvement (items 4-6), (3) rigor of development (items 7-14), (4) clarity 
and presentation (items 15-17), (5) applicability (items 18-21), and (6) editorial independence (items 
22-23) (Table 1). Each item is rated on a seven-point Likert scale, where seven correlates to strongly 
agree. It is important to note that a score of 1 does not necessarily mean that the item criterion was 
not fulfilled, instead this could represent a lack of relevant information available to the appraiser to 
assign an appropriate score. The instrument also asks appraisers to make two assessments; on the 
overall guideline quality, and whether they would recommend the CGs for use.  
Table 1 - Description of the AGREE II instrument 
Data analysis  
Descriptive statistics were used to summarise the domain and overall scores. A standardised score for 
the six domains and overall score was calculated by summing the scores of the individual items within 
each domain to achieve a percentage of the maximum possible score.  
The IBM SPSS Statistics version 24 package was used to calculate the agreement between the 
appraisers using intraclass correlation (ICC), which demonstrates the level of agreement between 
appraisers. A single measures, two-way random effects model was utilised. The range of ICC is 
between 0 and 1, where the closer to 1 a score is the smaller the variation between scores of raters 
on each item 12.  
RESULTS  
Clinical guidelines 
The three CGs included in this study had notably different intentions of use. In contrast to NICE and 
the EAU, ICI is not intended to be applied directly in clinical practice. Table 2 describes the 
characteristics of the CGs. 
Table 2: Description of Neurogenic bladder (NLUTD) clinical guidelines 
Scaled domain scores are presented in Table 3. The NICE CGs were deemed to be of the highest 
quality (overall score of 92%), they scored highest in stakeholder involvement domain (94%), and the 
lowest scoring domains were clarity of presentation and scope and purpose (86% in both domains). 
The EAU CGs received an overall score of 83%, the highest scoring domain was clarity of 
presentation (89%) and the lowest scoring domain was the applicability domain (63%). The ICI CGs 
achieved the lowest overall score amongst the CGs (75%). The highest scoring domain in this CG was 
clarity of presentation (94%) and the lowest scoring domain was applicability (54%). The ICC varied 
from low to excellent reliability (0.3-1); however, confidence intervals were insignificant in some 
domains (Table 4).  
Table 3:  Scaled domain percentages for AGREE II domains in the appraisal of neurogenic lower urinary 
tract dysfunction (NLUTD) guidelines 
Table 4: Intraclass correlation between two appraisers of neurogenic bladder guidelines 
95% CI not presented = CI crossed 0, therefore not significant ICC = <0.5 poor reliability, 0.5-<0.75 
moderate reliability, 0.75-0.9 good reliability, >0.9 excellent reliability.  
DISCUSSION 
To the best of the authors’ knowledge, this is the first study that assesses the quality of the NLUTD 
guidelines by using the AGREE II scores. Quality varied moderately across the AGREE II domains as well 
as between the NLUTD CGs. Amongst all CGs, the highest scoring domain was clarity of presentation 
and the lowest scoring was applicability. NICE achieved the highest overall score and the ICI achieved 
the lowest overall score, however all CGs were deemed to be of high quality, and were recommended 
for use in clinical practice (mostly with some modifications).  
The stakeholder representation domain evaluates the extent to which CGs have accurate 
representation from all relevant intended users, including professional groups and patients. Involving 
a broad range of stakeholders allows the integration of several unique perspectives on optimal 
healthcare, aids in the prioritisation of important topics, and minimises bias towards certain treatment 
options caused by conflicts of interest13. NICE scored exceptionally high in the stakeholder 
involvement domain (94%). The NICE CGs are developed not only by urological experts working in the 
field but also by a rigorous process of cross-collaboration with specialist and/or general physicians, 
HEOR specialists and patient groups. In contrast, the development group for both the EAU and ICI 
NLUTD CGs are made up almost exclusively of neuro-urological experts; they achieved 78% and 67% 
respectively. The EAU is slowly integrating patient perspective into their development process by 
engaging patient organisations, whereas the ICI acknowledge that increased efforts to incorporate the 
patient voice into their CGs is necessary. The transparency with which the stakeholders’ comments 
are incorporated into recommendations is an aspect all CGs need to improve upon.   
The most vital aspect in the formation of evidence-based recommendations is a comprehensive 
systematic review of available evidence 14. Recommendations in all three NLUTD CGs occasionally 
relied on expert opinion. Unfortunately, as the evidence base underlying NLUTD is composed of mainly 
observational studies, and trials with relatively small patient numbers and perceived weak 
methodological design, this cannot be avoided. The NICE systematic review process was deemed the 
most superior by the appraisers, thus achieved the highest score in the rigour of development domain 
(score 89%). The EAU previously employed a condensed process of evidence review; however, they 
recently announced a gradual implementation of the Cochrane methodology across their guideline 
panels. The 2017 version of the NLUTD CGs contained three new systematic reviews using this 
methodology. All three CGs used a validated grading system to describe the strengths and limitations 
of the underlying body of evidence.  
All CGs scored highly in the clarity of presentation domain, as the recommendations were easily 
identifiable, specific and unambiguous. It is important that all management options are presented, so 
end users can make fully informed clinical decisions. Although the ICI do not promote their CGs to be 
used directly in clinical practice, in reality they may be interpreted to be used in this way. Instead, the 
ICI GCs are endorsed as the reference work for the condition of interest, thus they consider an 
exhaustive number of management strategies compared to the other CGs15. This helped achieve the 
highest score in this domain (94%). The EAU lost points in this domain, as despite providing a thorough 
discussion on behavioural techniques, no graded recommendations were made for certain forms of 
management.  
It has been demonstrated that improvement in health outcomes is related to adherence to CGs16; 
however, due to multifaceted barriers to implementation, uptake of CGs has remained notoriously 
low.17 A 2007 survey sent out to Dutch urologists revealed that the EAU CGs for NLUTD were not 
systematically employed in clinical practice 18. The applicability domain measures the steps taken by 
the developers to improve uptake of the CGs and to what extent the resource implications of 
application have been considered. In light of the international scope of the ICI, the CGs achieved a low 
score for the applicability domain (54%). NICE and EAU have designated implementation teams with 
the aim of promoting uptake of CGs and overcoming barriers to implementation. They scored 90% 
and 60% respectively. Due to their national scope (UK only); it is easier for NICE to introduce strategies 
at a local level, including promoting a wide range of resources (e.g. educational presentations and 
patient leaflets), and engaging multiple organisations. For the same reason, NICE were able to consider 
the cost-effectiveness of treatments. Integrating economic evaluation into CGs is imperative given the 
ever increasing healthcare costs and the introduction of costly innovative products 19. The EAU was 
unique from the other CGs in that it has a designated team named the ‘Social Media (SoMe) working 
group’, who are responsible for promoting the guidelines on Facebook and Twitter. This is particularly 
important in an age where SoMe has become a frequent vehicle to disseminate medical information.  
The editorial independence domain reviews whether the funding body may have influenced the 
guideline content, and asks whether potential conflicts of interests (COI) have been adequately 
recorded and addressed. None of the CGs were pharmaceutical industry funded; however, some 
development members in all CGs declared financial relationships with industry. The NICE and EAU 
guidelines have specific policies on how to manage COI, thus scored a higher percentage in this domain 
(88% in both CGs). Both CGs employ cautionary measures such as excluding development members 
from voting or in the development of recommendations related to their area of COI20,21. A qualitative 
study into the NICE COI process determined that it was effective and transparent; however, as 
expected, it relied upon a process of self-reporting, which runs the risk of important omissions being 
made22. Some alternative opinion suggests that financial relationships with industry could provide 
unique and important expertise into the input of guideline development23.  
There are some limitations in this study that should be discussed. The AGREE II developers do not 
provide thresholds for what should be considered ‘low quality’ and ‘high quality’ CGs, thus 
interpretation of the resulting scores was ultimately a subjective exercise. Although the number of 
appraisers in this study was in line with the recommendations from the AGREE II collaborators, 
increasing this number could have improved the inter-rater reliability. One of the authors (MJD) was 
involved in the development of the ICI CGs, which could have introduced an element of bias; for this 
reason, MJD was not involved in the appraisal of any of the CGs for the current study. In addition, two 
authors work in Urology Research and Development based roles for a pharmaceutical company (ES & 
JN) and all authors based in the UK, which could affect the reliability of conclusions.  
CONCLUSIONS 
All CGs had their inherent advantages and disadvantages, although all were still deemed to be of high 
quality. The lower score overall for the ICI guidelines could partly be attributed to the contrasting 
purpose of development and intention of use as an international guidance document. NICE CGs were 
deemed to be of the highest quality due to attributes such as the involvement of multiple stakeholders 
and economic evaluation of treatment options. The EAU has some promising initiatives that will 
elevate the quality of their CGs in coming years. Incorporating the AGREE II instrument in the 
development of CGs and better collaboration between the ICI, NICE and EAU could improve the quality 
of NLUTD CGs and ultimately improve health outcomes for this important patient group. Institutions 
will have to overcome barriers such as ensuring the clinical and economic applicability of 
recommendations to a diverse range of healthcare systems across the globe.  
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